Abstract

The (8;21) translocation between AML1 and ETO is a frequently-observed nonrandom genetic alteration associated with acute myeloid leukemia (AML). AML1 upregulates a number of target genes critical to normal hematopoiesis, whereas the AML1-ETO fusion interferes with this trans- activation. We discovered that the fusion partner ETO binds to the human nuclear receptor co-repressor (N-CoR). Human N-CoR, which we cloned and sequenced in its entirety, encodes a 2,440 amino-acid polypeptide and has a central domain that binds ETO. N-CoR, mammalian Sin3 (mSin3), and histone deacetylase (HDAC1) form a complex that alters chromatin structure and mediates transcriptional repression by nuclear receptors and by a number of onco-regulatory proteins. We determined that ETO, either alone or as part of the AML1-ETO fusion, could bind to the N-CoR/mSin3/HDAC1 complex. As a result of this interaction, ETO can function as a potent repressor of transcription. Our observations provide a novel mechanism for how the AML1-ETO fusion inhibits expression of AML1-responsive target genes and disturbs normal hematopoiesis. Inhibitors of histone deacetylase may serve as a specific means of de-repressing hematopoietic target genes in patients with t(8;21) AML. - Leukemia, hematopoiesis, chromatin, histone deacetylase, transcription

  Funding Agency

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Intramural Research (Z01)
Project #
1Z01HL002344-04
Application #
6290427
Study Section
Special Emphasis Panel (HB)
Project Start
Project End
Budget Start
Budget End
Support Year
4
Fiscal Year
1999
Total Cost
Indirect Cost

  Institution

Name
National Heart, Lung, and Blood Institute
Department
Type
DUNS #
City
State
Country
United States
Zip Code